Medpace Holdings Inc Stock
Medpace Holdings Inc Stock
A loss of -2.350% shows a downward development for Medpace Holdings Inc.
Based on 4 Buy predictions and 5 Sell predictions the sentiment towards Medpace Holdings Inc is rather balanced.
However, we have a potential of 1.88% for Medpace Holdings Inc as the target price of 434 € is above the current price of 426.0 €.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Medpace Holdings Inc stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Medpace Holdings Inc in the next few years
Pros
?
M***** P*******
?
G***** c******* t* c**********
?
C******** o* t** e**********
Cons
?
S********** s********
?
W********* I********* f** t** n*** y****
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Medpace Holdings Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Medpace Holdings Inc | -2.350% | -1.412% | 8.012% | 62.348% | -11.728% | 141.497% | 185.906% |
| Galapagos N.V. | -0.160% | -5.008% | -12.536% | 14.313% | -13.409% | -30.629% | -62.948% |
| United Therapeutics | -0.200% | 0.327% | 4.602% | 98.224% | 14.908% | 138.813% | 194.012% |
| Ligand Pharmaceuticals | 0.550% | 1.676% | -0.546% | 97.826% | 9.639% | 177.863% | 49.425% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2025-04-26
Medpace Holdings, Inc. (MEDP) demonstrates a strong financial position as of Q2 2025, with key highlights including:
The overall financial trend is positive, driven by revenue growth and improving profitability.
Investors should consider these factors when evaluating Medpace Holdings, Inc., weighing the company's strong revenue and net income growth against its cash management and liquidity position.
Comments
Medpace (MEDP) is now covered by Royal Bank Of Canada. They set an "outperform" rating and a $522.00 price target on the stock.
Show more
Ratings data for MEDP provided by MarketBeat
Medpace (NASDAQ:MEDP) was upgraded by analysts at Robert W. Baird from a "neutral" rating to an "outperform" rating. They now have a $564.00 price target on the stock.
Show more
Ratings data for MEDP provided by MarketBeat
Medpace (NASDAQ:MEDP) had its price target raised by analysts at TD Cowen from $356.00 to $462.00. They now have a "sell" rating on the stock.
Show more
Ratings data for MEDP provided by MarketBeat